Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 49 of 65 · 3101 articles
This project explores how gut microbes and bile acids interact to shape immune cells in the ileum — a process that may affect inflammation in Crohn’s disease and other IBDs. Understanding these mechanisms could point to...
If surgeons can safely perform a primary bowel reconnection when they encounter an intra-abdominal abscess during Crohn surgery, some patients may avoid a temporary stoma and its associated morbidity.
The study identifies specific induction exposure targets and biomarkers tied to higher chances of deep remission at 12 months in children on anti-TNF therapy, which could inform earlier dose optimization to improve...
Automated, consistent scoring of the UCEIS could reduce subjectivity and variability in endoscopic assessment of ulcerative colitis, which matters for clinical trials, central reading, and potentially treatment decisions...
The study identifies a fungal β-glucan that reduced inflammation and altered the gut microbiome and short-chain fatty acids in a mouse model of ulcerative colitis, which could inform future nutritional or therapeutic...
Steroid dependency affects many people with ulcerative colitis and can change long-term treatment plans. This study explores clinical factors and uses an AI clustering method to visualize different risk patterns, which...
The coexistence of Peutz-Jeghers syndrome and Crohn's disease is exceptionally rare, and both conditions carry increased cancer risk. Patients, families, and clinicians need to know that there is little evidence to guide...
Altered NAD metabolism may influence inflammation and tissue repair in IBD; understanding host and microbial contributions could open new research directions for metabolic biomarkers or therapeutic targets.
The report suggests tofacitinib (a JAK inhibitor), alone or combined with ustekinumab, could be an effective option for some infants with treatment-refractory IOIBD — a population with few evidence-based alternatives. If...
Patients and caregivers considering or subject to insurance-driven switches from adalimumab originator to a biosimilar may want to know whether clinical status and medication continuation remain similar after switching.
ECCO 2026 presented multiple studies that could change IBD care across prevention, medical therapy (including pediatric data), complication‑directed strategies (perianal fistula), and technology‑assisted monitoring....
This matters because identifying microbiome patterns linked to infliximab response could help predict which children with IBD are more likely to benefit from the drug and guide personalized treatment decisions in the...
Perianal fistulizing Crohn's disease is difficult to treat and many patients have failed anti-TNF therapy. Evidence that ustekinumab achieves high clinical fistula response and remission rates in a real-world multicenter...
The study suggests quality-of-life and patient-reported measures can reveal a subgroup of UC patients in clinical remission who nevertheless have higher relapse risk, which could help personalize monitoring and care.
This mouse study identifies a novel peptide that reduced DSS-induced colitis and points to mast cells and fibroblast–mast cell interactions as potential therapeutic targets. It also showed additive benefit when combined...
This study compares many targeted IBD drugs indirectly to help clarify how subcutaneous vedolizumab stacks up against other biologics and newer oral therapies — information that could inform treatment discussions for...
Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from...
The analysis suggests genetic liability to IBD, particularly Crohn’s disease, may raise the risk of IgA vasculitis. This is relevant for understanding overlapping immune mechanisms and possible shared pathways between...
Nanotechnology is being heavily explored as a way to improve drug targeting, control release, and reduce systemic toxicity in IBD — topics that could shape future treatment options and research priorities.
Mood disorders commonly co-occur with chronic somatic diseases, including IBD; understanding shared mechanisms may explain worse outcomes and suggest multidisciplinary care needs.
The study explores a novel method to reduce gut oxidative stress — a contributor to IBD inflammation — by using an engineered probiotic to edit NOX2, which could point toward new therapeutic strategies if translated to...
Kidney dysfunction can occur in people with IBD and may be under-recognized. A validated prediction model could help clinicians identify IBD patients at higher risk and prompt earlier monitoring or interventions.
VEOIBD often has a strong genetic component and different clinical needs than adult IBD; this study shows genetic findings and treatment challenges in a Middle East pediatric center, which may affect diagnosis and access...
Intestinal fibrosis (stricture) is a serious, hard-to-treat complication of IBD/Crohn's disease. This preclinical study tests whether an antifibrotic drug used in lung fibrosis might reduce fibrosis in the gut, which...
This study reports real-world outcomes with granulocyte and monocyte adsorptive apheresis (GMA) in patients with refractory IBD, showing steroid-free remission by week 14 in about one-third of patients and continued...
Fecal incontinence is a distressing symptom that lowers quality of life and appears linked to active disease in UC. Knowing which patients are at higher risk can help clinicians focus assessment and symptom support.
Identifies a new molecular checkpoint (RADX versus IFI16) linking replication stress/genome instability to innate immune activation and intestinal inflammation, suggesting potential targets for future IBD treatments or...
This article suggests a naturally derived compound (isorhamnetin) identified from TCM may reduce inflammation in experimental ulcerative colitis and points to the Nrf2–PTGS2 pathway as a possible mechanism. That could...
The paper identifies microbiome-derived peptides that can directly block TLR4 signaling and reduce intestinal inflammation in mice; this reveals a new microbiome–immune mechanism that could inform future IBD treatments.
Metabolic syndrome appears common in this Tunisian IBD cohort (about one-third). MetS can affect overall health and may influence long-term outcomes for people with IBD, so awareness and cardiometabolic screening may be...
The study suggests a cellular redox pathway (selenium vs thiol axis) that is altered differently in Crohn's disease versus colorectal cancer, which could point to disease vulnerabilities and possible links to treatment...
The study suggests that in IBD the gut microbiome’s functional impact on immune signalling is shifted toward inflammation even when composition appears similar to controls.
Elevated pancreatic enzymes are relatively common in IBD and can reflect very different conditions (benign asymptomatic elevations, pancreatitis variants, or autoimmune pancreatitis). Recognizing phenotype-specific...
The study links a traditional herbal formula to improved colitis in mice and to changes in bile-acid metabolism through the FXR–FGF15 pathway, suggesting a mechanistic route that could inform future preclinical or...
Researchers are investigating RBM47 because it influences RNA processing and immune pathways that could modify inflammation and disease processes relevant to IBD. If borne out, RBM47 could become a biomarker or...
B cells and antibodies appear to play active, regulatory roles in gut inflammation and tissue organization in IBD. Understanding this axis could inform new therapies or biomarkers that change how inflammation is detected...
If you have IBD and joint symptoms, this study suggests your joint complaints may reflect measurable immune changes that partly overlap with spondyloarthritis, not just non-specific pain. That could mean joint symptoms...
This paper describes a new engineered, off-the-shelf regulatory T cell therapy (TRX103) designed to restore immune tolerance and that is already entering early clinical trials for treatment-refractory Crohn’s disease.
Fatigue is a common, disabling symptom in people with IBD with unclear causes. Finding reproducible immune or infectious signatures related to fatigue could point toward new research directions and, eventually, markers...
Researchers identified a defined pectin from Sanguisorba officinalis that reduced inflammatory cytokine release in cells and improved outcomes in a mouse colitis model, suggesting a new lead for IBD drug discovery.
Mitochondrial dysfunction may contribute to IBD symptoms and disease progression; therapies that protect or restore mitochondrial function could become future treatment strategies. People interested in complementary or...
Sarcopenia is common in Crohn's disease and is linked to worse outcomes; a simple GNRI-based prediction tool could help identify at-risk patients without routine CT scanning.
Finding monogenic causes in infants with congenital diarrheas or VEOIBD can directly affect diagnosis, genetic counseling, and management. Populations with higher consanguinity may have higher diagnostic yields for...
Infliximab dosing can be hard to personalize. This study shows that selecting pharmacokinetic models based on IBD type and severity can improve how well drug levels are predicted, which could help tailor dosing for...
Identifying genetic predictors of thiopurine-induced leukopenia could help prevent a serious drug side effect by improving pre-treatment genetic screening and dose decisions for people with IBD.
Perianal fistulas are a serious complication of Crohn’s disease with limited high-quality trial evidence. This randomized trial suggests ustekinumab may increase the chance of combined clinical and MRI remission at 12...
This trial is testing whether a rectally delivered probiotic can change the gut microbiome and promote mucosal healing in people with mild-to-moderate ulcerative colitis (and includes some Crohn's patients). If...
This trial is testing guselkumab (an IL‑23 inhibitor) in a real‑world UC cohort and will measure endoscopic and histologic remission at 48 weeks — outcomes that matter to people managing moderate‑to‑severe ulcerative...
